Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881125 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02881125 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 2 participants.
The verdict
NCT02881125, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of nortriptyline hydrochloride when given together with paclitaxel in treating patients with small cell carcinoma that has come back. Nortriptyline hydrochloride, may help disrupt survival signals and cause cancer cell death. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nortriptyline hydrochloride and paclitaxel may work better in treating patients with small cell carcinoma.
Interventions
- DRUG Paclitaxel
- DRUG Nortriptyline Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-11-03 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02881125
The ClinicalTrials.gov registry entry for NCT02881125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02881125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02881125 about?
NCT02881125 is a clinical study titled "Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma". This phase I trial studies the side effects and best dose of nortriptyline hydrochloride when given together with paclitaxel in treating patients with small cell carcinoma that has come back. Nortriptyline hydrochloride, may help disrupt survival signals and cause cancer cell death. Drugs used in ch...
What is the current status of trial NCT02881125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-11-03. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02881125?
The interventions under investigation include: Paclitaxel (DRUG), Nortriptyline Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02881125?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.